Wasiak, S., Dzobo, K. E., Rakai, B. D., Kaiser, Y., Versloot, M., Bahjat, M., . . . Kulikowski, E. (2020). BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. Clin Epigenetics.
Citação norma ChicagoWasiak, Sylwia, et al. "BET Protein Inhibitor Apabetalone (RVX-208) Suppresses Pro-inflammatory Hyper-activation of Monocytes From Patients With Cardiovascular Disease and Type 2 Diabetes." Clin Epigenetics 2020.
Citação norma MLAWasiak, Sylwia, et al. "BET Protein Inhibitor Apabetalone (RVX-208) Suppresses Pro-inflammatory Hyper-activation of Monocytes From Patients With Cardiovascular Disease and Type 2 Diabetes." Clin Epigenetics 2020.